# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and maintains $...
Financial Results: Cash Position: As of December 31, 2023, Checkpoint's cash and cash equivalents totaled $4.9 million, ...
The Nasdaq 100 closed higher by around 300 points on Friday. Investors, meanwhile, focused on some notable insider trades.
B. Riley Securities analyst Mayank Mamtani maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the price t...
B. Riley Securities analyst Mayank Mamtani maintains Checkpoint Therapeutics (NASDAQ:CKPT) with a Buy and lowers the price t...
Shares of Compugen Ltd. (NASDAQ: CGEN) shares rose sharply during Tuesday’s session after Gilead announced an agreement with t...